Welcome to our dedicated page for EVOGENE LTD. news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on EVOGENE LTD. stock.
Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a leading computational biology company leveraging big data and artificial intelligence to revolutionize the development of life-science-based products. The company, headquartered in Rehovot, Israel, employs cutting-edge technologies to increase the probability of success while reducing development time and cost across multiple market segments including human health, agriculture, and industrial applications. Evogene has established three unique tech-engines - MicroBoost AI, ChemPass AI, and GeneRator AI - each focused on products based on microbes, small molecules, and genetic elements respectively.
The company operates through several subsidiaries that utilize these tech-engines:
- Biomica Ltd.: Develops microbiome-based therapeutics for diseases such as antibiotic-resistant bacteria, cancer, and gastrointestinal disorders.
- Lavie Bio Ltd.: Focuses on microbiome-based ag-biologicals to enhance crop yield and sustainability.
- AgPlenus Ltd.: Innovates in sustainable crop protection products.
- Canonic Ltd.: Develops medical cannabis products.
- Casterra Ag Ltd.: Produces high-yield castor seeds for biofuels and other industrial uses.
Evogene's recent achievements include securing new seed production agreements for Casterra, advancing clinical trials for Biomica's immuno-oncology candidate BMC128, and extending validation trials for Lavie Bio's biofungicides in collaboration with Bayer AG. Evogene has been proactive in addressing its Nasdaq listing compliance and continues to prioritize innovation through strategic partnerships and collaborative ventures. For more information, please visit www.evogene.com.
Evogene's subsidiary, Lavie Bio, has launched its first microbiome-based inoculant, result™, aimed at improving wheat yield. Set for limited marketing in North Dakota for the 2022 spring wheat season, result™ is projected to enhance farmers' profits by up to 50%, offering an additional $20 per acre. Field trials indicate a potential increase of 3-4 bushels per acre compared to industry benchmarks. Lavie Bio plans to expand distribution and production capabilities, leveraging its BDD platform that utilizes AI and big data for product development.
On October 27, 2021, Biomica Ltd., a subsidiary of Evogene (NASDAQ: EVGN), and Rambam Health Care Campus announced a clinical trial agreement to initiate a first in-human proof-of-concept study for BMC128, Biomica's innovative drug candidate targeting refractory cancers. The trial aims to evaluate the safety and tolerability of BMC128 in combination with anti-PD-1 therapy in patients with Non-small Cell Lung Cancer, Melanoma, or Renal Cell Carcinoma. This study follows promising preclinical results showing enhanced anti-tumor activity, pending approval from the Israeli Ministry of Health.
Evogene Ltd. (NASDAQ: EVGN) has announced that it will release its third quarter 2021 financial results on November 17, 2021. The CEO of Canonic Ltd., a subsidiary of Evogene, will participate in a conference call to discuss the results at 9:00 AM ET. Investors can access the call via phone or live webcast on the company’s website. A replay will be available shortly after the call until November 19, 2021. Evogene focuses on computational biology to enhance product discovery in multiple life-science industries.
Canonic Ltd., a wholly-owned subsidiary of Evogene Ltd. (NASDAQ: EVGN), has launched its first medical cannabis products, G200 and G150, ahead of schedule due to positive patient feedback during a pre-launch campaign. The products, categorized under T20/C4 and T15/C3, will be widely available in Israeli pharmacies immediately. Israel's medical cannabis market is valued at approximately $260 million annually, with over 100,000 licensed patients expected to double by 2025. Both products showcase high THC levels developed through Evogene's computational platform.
Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), has announced a distribution agreement with United Agronomy for its microbial inoculant product LAV.211. The agreement aims to enhance the commercialization of LAV.211 in North Dakota, targeting the 2022 spring wheat season. LAV.211 is designed to improve nutrient uptake and increase crop yield while promoting environmental sustainability. Initial testing has shown positive results, and both companies expect this partnership to benefit local farmers and enhance profitability.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will participate in a "Fireside Chat" at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. The interview will take place on September 28, 2021, at 10:40 am EST. Haviv will discuss Evogene's innovative technologies and product development strategies across its subsidiaries. Interested investors can access the webcast at this link and can arrange meetings with Mr. Haviv through the investor relations team.
Evogene Ltd. (NASDAQ: EVGN) announced that its President and CEO, Ofer Haviv, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 9-15, 2021. The presentation will take place on September 9, 2021, at 07:30 am EST, focusing on Evogene's innovative technologies and product discovery engines. Investors interested in meeting Mr. Haviv can contact Evogene's Investor Relations team. Evogene leverages its Computational Predictive Biology platform to advance life-science products in human health and agriculture.
Canonic Ltd, a subsidiary of Evogene, has announced the pre-launch of its first-generation medical cannabis products, branded as G-nnovation, in Israel. The products, which focus on high THC content, will be sold to a limited number of licensed patients through Telepharma pharmacy. Full commercial launch is expected in 2022. The Israel medical cannabis market is valued at approximately $260 million, with 100,000 licensed patients in July 2021. Canonic aims to become a global leader in medical cannabis, leveraging Evogene's advanced computational biology capabilities.
Evogene Ltd. (NASDAQ: EVGN) reported its financial results for H1 2021, revealing a cash position of $65.4 million. The company is advancing on its strategy to enhance shareholder value via its subsidiaries, considering spin-offs for independent trading. Biomica showcased significant anti-tumor activity for its candidate BMC128, with plans for a proof-of-concept trial. However, cash usage increased to $11.3 million in H1 2021, driven by product development investments, and net loss rose to $6.9 million in Q2 2021, compared to $4.8 million in Q2 2020.
Evogene Ltd. (NASDAQ: EVGN) announced that President and CEO Ofer Haviv will present at the Jefferies Virtual Industrials Conference on August 3, 2021, at 09:00 AM EST. The presentation will highlight Evogene's disruptive technologies and tailored engines for product discovery across its subsidiaries. Investors interested in meeting Mr. Haviv can contact Evogene's Investor Relations team. Evogene is focused on revolutionizing life-science product development using its Computational Predictive Biology platform, targeting sectors like human health and agriculture.
FAQ
What is the current stock price of EVOGENE LTD. (EVGN)?
What is the market cap of EVOGENE LTD. (EVGN)?
What does Evogene Ltd. do?
Where is Evogene Ltd. headquartered?
What are Evogene's main technology platforms?
Who are some of Evogene's subsidiaries?
What is the focus of Biomica Ltd.?
What recent partnerships has Evogene engaged in?
How is Evogene addressing its Nasdaq listing compliance?
What are some recent achievements of Evogene Ltd.?
Where can I find more information about Evogene Ltd.?
What market segments does Evogene target?
